- Home
- TVRD vs DYAI Comparison
TVRD vs DYAI Comparison
Compare TVRD & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVRD | DYAI |
|---|---|---|
| Founded | 2017 | 1979 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 32.5M |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | TVRD | DYAI |
|---|---|---|
| Price | $2.84 | $0.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $29.50 | $3.00 |
| AVG Volume (30 Days) | 45.6K | ★ 255.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,090,345.00 |
| Revenue This Year | N/A | $122.79 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.75 | $0.65 |
| 52 Week High | $43.65 | $1.35 |
Technical Indicators
Market Signals| Indicator | TVRD | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 42.57 |
| Support Level | N/A | N/A |
| Resistance Level | $4.32 | $0.91 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 2.34 | 15.68 |
Price Performance
Historical ComparisonAbout TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.